Forgot your password?
Forgot your username?
JOIN THE LPMA
FIND A PSYCHIATRIST
FOR THE PUBLIC
News, Information & Links
Continuing Medical Education
LPMA News & Updates
APA News & Updates
Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks
Find a Psychiatrist
Resources for the Public
Calendar of Events
A.G. Schneiderman Announces Settlement With Emblem Health For Wrongly Denying Mental Health And Substance Abuse Treatment For Thousands Of New York Members |
Click here to read the article
| The APA is now accepting abstract submissions for its
168th Annual Meeting to be held in Toronto, Ontario, Canada. May 16-21, 2015
. The theme of the meeting is
Psychiatry: Integrating Body and Mind, Heart and Soul.
The submission deadline is
Tuesday, September 9, 2014.
To submit an abstract, review the types of abstracts to be submitted, or learn more about the 2015 Annual Meeting please click
Psychiatric News Alert
The Voice of the
American Psychiatric Association
and the Psychiatric Community
FDA Approves Psychiatric Drug Combo for Weight Loss
The Food and Drug Administration (FDA) has approved Contrave—a combination drug consisting of naltrexone (an opioid receptor antagonist) and bupropion extended-release (an antidepressant and pharmacological smoking-cessation aid) —as a new treatment option for weight loss in people who have a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with one weight-related condition such as hypertension or type II diabetes.
The effectiveness of Contrave was measured in multiple clinical trials with approximately 4,500 obese and overweight individuals, with and without significant weight-related conditions, who were on a reduced-calorie diet and a physical activity regimen. Results in a trial with nondiabetic patients, showed that 42% of participants taking Contrave were able to shed at least 5% of their body weight in a year, while only 17% of patients treated with placebo were able to do so. In a clinical trial with diabetes patients, those taking the combination drug where twice as likely to lose 5% of their body weight within a year than were control subjects. Most common adverse reactions reported included nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.
Because the medication contains bupropion, it has a boxed warning for increased risk of suicidal behaviors and serious neuropsychiatric events. The exact neurochemical effects of the drug leading to weight loss are not yet fully understood, according to the...
Registration is Open!
Louisiana Psychiatric Medical Association &
Southern Psychiatric Association
Psychiatry in a Changing Healthcare Landscape
September 10-14, 2014
Royal Sonesta Hotel
New Orleans, LA
Click on the Calendar of Events Above for Schedule & Registration Details
LPMA • 9655 Perkins Rd. #C-152 • Baton Rouge, LA 70810 • PH: 225-761-3718 • FAX: 228-215-1256 •
Web Design by
Bruner and Company